Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

SMYD3 (SET and MYND domain containing 3)

Written2010-07Xue-Gang Luo, Shu Guo, Tong-Cun Zhang
College of Bioengineering, Tianjin University of Science, Technology, Tianjin, China

(Note : for Links provided by Atlas : click)

Identity

Alias_namesZNFN3A1
ZMYND1
zinc finger
Alias_symbol (synonym)KMT3E
HGNC (Hugo) SMYD3
LocusID (NCBI) 64754
Atlas_Id 46100
Location 1q44  [Link to chromosome band 1q44]
Location_base_pair Starts at 245912642 and ends at 246670644 bp from pter ( according to hg19-Feb_2009)  [Mapping SMYD3.png]
Local_order The human SMYD3 gene maps on 1q44 between the LOC100132379 and the KIF26B loci.
Fusion genes
(updated 2016)
COBLL1 (2q24.3) / SMYD3 (1q44)CXXC5 (5q31.2) / SMYD3 (1q44)KIF26B (1q44) / SMYD3 (1q44)
RBFOX1 (16p13.3) / SMYD3 (1q44)RPS12 (6q23.2) / SMYD3 (1q44)SMYD3 (1q44) / ARHGAP5 (14q12)
SMYD3 (1q44) / EDARADD (1q42.3)SMYD3 (1q44) / ELOVL1 (1p34.2)SMYD3 (1q44) / PDIA6 (2p25.1)
SMYD3 (1q44) / SMYD3 (1q44)SMYD3 (1q44) / TFB2M (1q44)SMYD3 (1q44) / WLS (1p31.3)
SMYD3 (1q44) / ZNF695 (1q44)

DNA/RNA

 
  Genomic organization of SMYD3. The SMYD3 gene is comprised of 12 exons and encodes for two alternatively transcript variants that use different first exon and promoter.
Description The SMYD3 gene is comprised of 12 exons, spanning 757.8 kb on chromosome 1q44. Two transcript variants were encoded using different first exon and promoter.
A variable number of tandem repeats (VNTR) polymorphism in E2F-1-binding element in the promoter region of SMYD3 transcript variant 1 has been shown to be significantly associated with an increased risk of colorectal cancer, hepatocellular carcinoma and breast cancer in Japanese population (Tsuge et al., 2005). It is also shown that this VNTR polymorphism might be a susceptibility factor for human esophageal squamous cell carcinoma in relation to tobacco smoking (Wang H et al., 2008). However, it seemed that this polymorphism was not associated with the cancer risk in all the races in the world (Frank et al., 2006; Wang et al., 2007).
A copy-number variation (CNV) on chromosome 1 was observed to be proximal to SMYD3 that displayed high expression in the lymphoblastoid cell lines, and this CNV was significantly associated with 1-beta-D-arabinofuranosylcytosine cytotoxicity (Kalari et al., 2010).
Transcription The SMYD3 gene mainly has two transcript variants of 1641 and 1469 bp, each comprising 12 exons. They differ for the alternative usage of the different first exon and promoter. The variant 2 is shorter at the N-terminus, compared to the variant 1. Besides, there was a report showed that another SMYD3 transcript variant, termed SMYD3-NY, was detected in adult human testis and spermatozoa using the methods of hybridization with a human cDNA microarray (Zhou et al., 2005). However, SMYD3-NY has not been further confirmed with experimental evidence yet.
Pseudogene Not yet described.

Protein

 
  Protein domains of SMYD3. SMYD3 has two isoforms. The isoform 2 (369 amino acids) just lacks 59 amino acid at the N-terminus of the isoform 1 (428 amino acids).
Description The 1641 bp transcript variant 1 encodes a 428 amino acids protein containing a zf-MYND domain (49-87) and a SET domain (148-239), the transcript variant 2 uses a downstream translational start codon and encodes a 369 amino acids protein which is 100% identical with the 60-428 region of the isoform 1.
It has been shown that human cancer cells also express a cleaved form of SMYD3 lacking the 34 amino acids in the N-terminal region of the full-length SMYD3 isoform 1. It seems that the N-terminal region of SMYD3 isoform 1 plays an important role for the regulation of its methyltransferase activity, and the cleavage of 34 amino acids in the N-terminal region or interaction with heat shock protein 90 alpha (HSP90alpha) may enhance the histone methyltransferase (HMTase) activity compared to the full-length protein (Silva et al., 2008).
Expression SMYD3 is frequently up-regulated in colorectal carcinoma, hepatocellular carcinoma and breast cancer (Hamamoto et al., 2004; Hamamoto et al., 2006). miR-124 can down-regulate SMYD3 through binding to 3' UTR of SMYD3 protein (Furuta et al., 2010).
Localisation The SMYD3 protein is located mainly in the cytoplasm when the cells are arrested at G0/G1, but accumulated in the nuclei at S phase and G2/M (Hamamoto et al., 2004).
Function SMYD3 is a SET-domain-containing lysine histone methyltransferase which has been regarded as an important factor in carcinogenesis. Formed a complex with RNA polymerase II through an interaction with the RNA helicase HELZ, SMYD3 specifically methylates histone H3 at lysine 4 and activates the transcription of a set of downstream genes (including of Nkx2.8, hTERT, WNT10B, VEGFR1, c-Met, etc) containing a "5' - CCCTCC - 3'" or "5' - GGAGGG - 3'" sequence in the promoter region, and these activities require protein cofactors HSP90alpha (Hamamoto et al., 2004; Liu et al., 2007; Hamamoto et al., 2006; Kunizaki et al., 2007; Zou et al., 2009). Enhanced expression of SMYD3 is essential for the growth of many cancer cells (such as colorectal carcinoma, hepatocellular carcinoma, breast cancer, etc), and it also could stimulate cell adhesion and migration, whereas suppression of SMYD3 by RNAi or other reagents induces apoptosis and inhibits cell proliferation and migration (Hamamoto et al., 2004; Hamamoto et al., 2006; Luo et al., 2007; Wang SZ et al., 2008; Zou et al., 2009; Chen et al., 2007; Luo et al., 2010).
SMYD3 may be an important coactivator of estrogen receptor (ER) in the estrogen signal pathway. It can directly interact with the ligand binding domain of ER, in turn augments ER target gene expression via histone H3-K4 methylation (Kim et al., 2009). Besides, it has been shown that SMYD3 could interact with Jab1 in yeast cells and in vitro, and might be required for Jab1-mediated enhancement of hemotopoietic progenitors cells (Mori et al., 2008).
Homology SMYD3 displays structural homologies with other members of the SMYD histone methyltransferase family, such as the SMYD1 (30% identity, 50% similarity), SMYD2 (32% identity, 52% similarity), SMYD4 and SMYD5.

Mutations

Note Not yet described. A VNTR polymorphism in the 5' flanking region of SMYD3 has been reported as we mentioned in the "DNA Description" section.

Implicated in

Note
  
Entity Colorectal carcinoma
Note SMYD3 expression is markedly elevated in colorectal cancers, and this upregulation enhances the growth of tumor cells (Hamamoto et al., 2004).
  
  
Entity Hepatocellular carcinoma
Note SMYD3 was found to be overexpressed in human hepatocarcinoma cells, and silencing of SMYD3 by RNAi could inhibit cell proliferation and migration (Hamamoto et al., 2004; Zou et al., 2009; Chen et al., 2007). miR-124, usually be epigenetically silenced in hepatocarcinoma cells, could downregulate SMYD3 expression and inhibit cell growth (Furuta et al., 2010). Hepatitis B virus X protein could upregulate SMYD3 expression in HepG2 hepatocellular carcinoma cell lines, and this effect might promote the progress of hepatoma (Yang et al., 2009).
  
  
Entity Breast cancer
Note SMYD3 overexpression was observed in the great majority of breast cancer tissues, and suppression of SMYD3 by RNAi or other reagents could inhibit cell proliferation and migration (Hamamoto et al., 2006; Luo et al., 2010). Furthermore, SMYD3 was identified as a new coactivator for ER and was required in estrogen signal pathway (Kim et al., 2009).
  
  
Entity Cervical carcinoma
Note Suppression of SMYD3 by RNAi could reduce cell proliferation, colony formation and migration/invasion activity, and induces apoptosis in Hela cervical carcinoma cells (Wang SZ et al., 2008).
  
  
Entity Multiple myeloma
Note Triptolide, an antitumor Chinese herb extracted ingredient, could decrease the expression of SMYD3 and inhibit the proliferation of multiple myeloma cell line U266 in a time- and dose-dependent manner (Zhao et al., 2010).
  
  
Entity Esophageal squamous cell carcinoma
Note A VNTR polymorphism in E2F-1-binding element in the promoter region of SMYD3 transcript variant 1 was observed to be a susceptibility factor for human esophageal squamous cell carcinoma in relation to tobacco smoking (Wang H et al., 2008).
  

Breakpoints

Note A breakpoint on 1q44 is located in the SMYD3 gene (Aktas et al., 2010).

Bibliography

Derivative chromosome 1 and GLUT1 deficiency syndrome in a sibling pair.
Aktas D, Utine EG, Mrasek K, Weise A, von Eggeling F, Yalaz K, Posorski N, Akarsu N, Alikasifoglu M, Liehr T, Tuncbilek E.
Mol Cytogenet. 2010 May 28;3(1):10.
PMID 20509907
 
Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration.
Chen LB, Xu JY, Yang Z, Wang GB.
World J Gastroenterol. 2007 Nov 21;13(43):5718-24.
PMID 17963297
 
Variable number of tandem repeats polymorphism in the SMYD3 promoter region and the risk of familial breast cancer.
Frank B, Hemminki K, Wappenschmidt B, Klaes R, Meindl A, Schmutzler RK, Bugert P, Untch M, Bartram CR, Burwinkel B.
Int J Cancer. 2006 Jun 1;118(11):2917-8.
PMID 16381023
 
miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J.
Carcinogenesis. 2010 May;31(5):766-76. Epub 2009 Oct 20.
PMID 19843643
 
Enhanced SMYD3 expression is essential for the growth of breast cancer cells.
Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, Furukawa Y.
Cancer Sci. 2006 Feb;97(2):113-8.
PMID 16441421
 
Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach.
Kalari KR, Hebbring SJ, Chai HS, Li L, Kocher JP, Wang L, Weinshilboum RM.
BMC Genomics. 2010 Jun 4;11:357.
PMID 20525348
 
Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription.
Kim H, Heo K, Kim JH, Kim K, Choi J, An W.
J Biol Chem. 2009 Jul 24;284(30):19867-77. Epub 2009 Jun 9.
PMID 19509295
 
The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
Kunizaki M, Hamamoto R, Silva FP, Yamaguchi K, Nagayasu T, Shibuya M, Nakamura Y, Furukawa Y.
Cancer Res. 2007 Nov 15;67(22):10759-65.
PMID 18006819
 
The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
Liu C, Fang X, Ge Z, Jalink M, Kyo S, Bjorkholm M, Gruber A, Sjoberg J, Xu D.
Cancer Res. 2007 Mar 15;67(6):2626-31.
PMID 17363582
 
SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells.
Luo XG, Ding Y, Zhou QF, Ye L, Wang SZ, Xi T.
J Biosci Bioeng. 2007 May;103(5):444-50.
PMID 17609160
 
Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
Luo XG, Zou JN, Wang SZ, Zhang TC, Xi T.
IUBMB Life. 2010 Mar;62(3):194-9.
PMID 20039369
 
Stable form of JAB1 enhances proliferation and maintenance of hematopoietic progenitors.
Mori M, Yoneda-Kato N, Yoshida A, Kato JY.
J Biol Chem. 2008 Oct 24;283(43):29011-21. Epub 2008 Jul 30.
PMID 18667426
 
Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells.
Silva FP, Hamamoto R, Kunizaki M, Tsuge M, Nakamura Y, Furukawa Y.
Oncogene. 2008 Apr 24;27(19):2686-92. Epub 2007 Nov 12.
PMID 17998933
 
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.
Tsuge M, Hamamoto R, Silva FP, Ohnishi Y, Chayama K, Kamatani N, Furukawa Y, Nakamura Y.
Nat Genet. 2005 Oct;37(10):1104-7. Epub 2005 Sep 11.
PMID 16155568
 
Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking.
Wang H, Liu Y, Tan W, Zhang Y, Zhao N, Jiang Y, Lin C, Hao B, Zhao D, Qian J, Lu D, Jin L, Wei Q, Lin D, He F.
Cancer Sci. 2008 Apr;99(4):787-91. Epub 2008 Feb 21.
PMID 18294291
 
Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cell growth and invasion in vitro.
Wang SZ, Luo XG, Shen J, Zou JN, Lu YH, Xi T.
BMB Rep. 2008 Apr 30;41(4):294-9.
PMID 18452649
 
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
Wang XQ, Miao X, Cai Q, Garcia-Barcelo MM, Fan ST.
Exp Oncol. 2007 Mar;29(1):71-3.
PMID 17431393
 
Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells.
Yang L, He J, Chen L, Wang G.
Med Oncol. 2009 Dec;26(4):445-51. Epub 2008 Dec 13.
PMID 19082926
 
Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells.
Zhao F, Chen Y, Li R, Zeng R, Wen L, Liu Y, Zhang C.
Eur J Pharmacol. 2010 Jun 12. [Epub ahead of print]
PMID 20547150
 
SMYD3-NY, a novel SMYD3 mRNA transcript variant, may have a role in human spermatogenesis.
Zhou Z, Ren X, Huang X, Lu L, Xu M, Yin L, Li J, Sha J.
Ann Clin Lab Sci. 2005 Summer;35(3):270-7.
PMID 16081583
 
Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF.
Zou JN, Wang SZ, Yang JS, Luo XG, Xie JH, Xi T.
Cancer Lett. 2009 Jul 18;280(1):78-85. Epub 2009 Mar 24.
PMID 19321255
 

Citation

This paper should be referenced as such :
Luo, XG ; Guo, S ; Zhang, TC
SMYD3 (SET, MYND domain containing 3)
Atlas Genet Cytogenet Oncol Haematol. 2011;15(4):344-346.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/SMYD3ID46100ch1q44.html


Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 1 ]
  Lung: Translocations in Squamous Cell Carcinoma


External links

Nomenclature
HGNC (Hugo)SMYD3   15513
Cards
AtlasSMYD3ID46100ch1q44
Entrez_Gene (NCBI)SMYD3  64754  SET and MYND domain containing 3
AliasesKMT3E; ZMYND1; ZNFN3A1; bA74P14.1
GeneCards (Weizmann)SMYD3
Ensembl hg19 (Hinxton)ENSG00000185420 [Gene_View]  chr1:245912642-246670644 [Contig_View]  SMYD3 [Vega]
Ensembl hg38 (Hinxton)ENSG00000185420 [Gene_View]  chr1:245912642-246670644 [Contig_View]  SMYD3 [Vega]
ICGC DataPortalENSG00000185420
TCGA cBioPortalSMYD3
AceView (NCBI)SMYD3
Genatlas (Paris)SMYD3
WikiGenes64754
SOURCE (Princeton)SMYD3
Genetics Home Reference (NIH)SMYD3
Genomic and cartography
GoldenPath hg19 (UCSC)SMYD3  -     chr1:245912642-246670644 -  1q44   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)SMYD3  -     1q44   [Description]    (hg38-Dec_2013)
EnsemblSMYD3 - 1q44 [CytoView hg19]  SMYD3 - 1q44 [CytoView hg38]
Mapping of homologs : NCBISMYD3 [Mapview hg19]  SMYD3 [Mapview hg38]
OMIM608783   
Gene and transcription
Genbank (Entrez)AB057595 AK023594 AK024733 AK289605 AW173130
RefSeq transcript (Entrez)NM_001167740 NM_022743
RefSeq genomic (Entrez)NC_000001 NC_018912 NT_167186 NW_004929294
Consensus coding sequences : CCDS (NCBI)SMYD3
Cluster EST : UnigeneHs.567571 [ NCBI ]
CGAP (NCI)Hs.567571
Alternative Splicing GalleryENSG00000185420
Gene ExpressionSMYD3 [ NCBI-GEO ]   SMYD3 [ EBI - ARRAY_EXPRESS ]   SMYD3 [ SEEK ]   SMYD3 [ MEM ]
Gene Expression Viewer (FireBrowse)SMYD3 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)64754
GTEX Portal (Tissue expression)SMYD3
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ9H7B4   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ9H7B4  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ9H7B4
Splice isoforms : SwissVarQ9H7B4
Catalytic activity : Enzyme2.1.1.43 [ Enzyme-Expasy ]   2.1.1.432.1.1.43 [ IntEnz-EBI ]   2.1.1.43 [ BRENDA ]   2.1.1.43 [ KEGG ]   
PhosPhoSitePlusQ9H7B4
Domaine pattern : Prosite (Expaxy)SAM_MT43_2 (PS51574)    SET (PS50280)    ZF_MYND_1 (PS01360)    ZF_MYND_2 (PS50865)   
Domains : Interpro (EBI)Hist-Lys_N-MeTrfase_Smyd3    SET_dom    Znf_MYND   
Domain families : Pfam (Sanger)SET (PF00856)    zf-MYND (PF01753)   
Domain families : Pfam (NCBI)pfam00856    pfam01753   
Domain families : Smart (EMBL)SET (SM00317)  
Conserved Domain (NCBI)SMYD3
DMDM Disease mutations64754
Blocks (Seattle)SMYD3
PDB (SRS)3MEK    3OXF    3OXG    3OXL    3PDN    3QWP    3RU0    5CCL    5CCM   
PDB (PDBSum)3MEK    3OXF    3OXG    3OXL    3PDN    3QWP    3RU0    5CCL    5CCM   
PDB (IMB)3MEK    3OXF    3OXG    3OXL    3PDN    3QWP    3RU0    5CCL    5CCM   
PDB (RSDB)3MEK    3OXF    3OXG    3OXL    3PDN    3QWP    3RU0    5CCL    5CCM   
Structural Biology KnowledgeBase3MEK    3OXF    3OXG    3OXL    3PDN    3QWP    3RU0    5CCL    5CCM   
SCOP (Structural Classification of Proteins)3MEK    3OXF    3OXG    3OXL    3PDN    3QWP    3RU0    5CCL    5CCM   
CATH (Classification of proteins structures)3MEK    3OXF    3OXG    3OXL    3PDN    3QWP    3RU0    5CCL    5CCM   
SuperfamilyQ9H7B4
Human Protein AtlasENSG00000185420
Peptide AtlasQ9H7B4
HPRD12297
IPIIPI00165073   IPI00514981   IPI00643755   IPI01018805   IPI00877589   IPI00880129   
Protein Interaction databases
DIP (DOE-UCLA)Q9H7B4
IntAct (EBI)Q9H7B4
FunCoupENSG00000185420
BioGRIDSMYD3
STRING (EMBL)SMYD3
ZODIACSMYD3
Ontologies - Pathways
QuickGOQ9H7B4
Ontology : AmiGORNA polymerase II core promoter sequence-specific DNA binding  RNA polymerase II core binding  RNA polymerase II intronic transcription regulatory region sequence-specific DNA binding  nucleoplasm  cytoplasm  nucleosome assembly  negative regulation of protein kinase activity  myotube cell development  histone-lysine N-methyltransferase activity  histone-lysine N-methyltransferase activity  positive regulation of peptidyl-serine phosphorylation  histone lysine methylation  establishment of protein localization  positive regulation of transcription from RNA polymerase II promoter  metal ion binding  cellular response to dexamethasone stimulus  
Ontology : EGO-EBIRNA polymerase II core promoter sequence-specific DNA binding  RNA polymerase II core binding  RNA polymerase II intronic transcription regulatory region sequence-specific DNA binding  nucleoplasm  cytoplasm  nucleosome assembly  negative regulation of protein kinase activity  myotube cell development  histone-lysine N-methyltransferase activity  histone-lysine N-methyltransferase activity  positive regulation of peptidyl-serine phosphorylation  histone lysine methylation  establishment of protein localization  positive regulation of transcription from RNA polymerase II promoter  metal ion binding  cellular response to dexamethasone stimulus  
REACTOMEQ9H7B4 [protein]
REACTOME Pathways3214841 [pathway]   
NDEx NetworkSMYD3
Atlas of Cancer Signalling NetworkSMYD3
Wikipedia pathwaysSMYD3
Orthology - Evolution
OrthoDB64754
GeneTree (enSembl)ENSG00000185420
Phylogenetic Trees/Animal Genes : TreeFamSMYD3
HOVERGENQ9H7B4
HOGENOMQ9H7B4
Homologs : HomoloGeneSMYD3
Homology/Alignments : Family Browser (UCSC)SMYD3
Gene fusions - Rearrangements
Fusion : MitelmanCOBLL1/SMYD3 [2q24.3/1q44]  [t(1;2)(q44;q24)]  
Fusion : MitelmanSMYD3/EDARADD [1q44/1q42.3]  [t(1;1)(q42;q44)]  
Fusion : MitelmanSMYD3/ELOVL1 [1q44/1p34.2]  [t(1;1)(p34;q44)]  
Fusion : MitelmanSMYD3/WLS [1q44/1p31.3]  [t(1;1)(p31;q44)]  
Fusion: TCGACOBLL1 2q24.3 SMYD3 1q44 LUSC
Fusion: TCGAKIF26B 1q44 SMYD3 1q44 HNSC LUSC
Fusion: TCGASMYD3 1q44 EDARADD 1q42.3 LUAD
Fusion: TCGASMYD3 1q44 TFB2M 1q44 BRCA
Fusion: TCGASMYD3 1q44 WLS 1p31.3 BRCA
Fusion: TCGASMYD3 1q44 ZNF695 1q44 HNSC
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerSMYD3 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)SMYD3
dbVarSMYD3
ClinVarSMYD3
1000_GenomesSMYD3 
Exome Variant ServerSMYD3
ExAC (Exome Aggregation Consortium)SMYD3 (select the gene name)
Genetic variants : HAPMAP64754
Genomic Variants (DGV)SMYD3 [DGVbeta]
DECIPHER (Syndromes)1:245912642-246670644  ENSG00000185420
CONAN: Copy Number AnalysisSMYD3 
Mutations
ICGC Data PortalSMYD3 
TCGA Data PortalSMYD3 
Broad Tumor PortalSMYD3
OASIS PortalSMYD3 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICSMYD3  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDSMYD3
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch SMYD3
DgiDB (Drug Gene Interaction Database)SMYD3
DoCM (Curated mutations)SMYD3 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)SMYD3 (select a term)
intoGenSMYD3
NCG5 (London)SMYD3
Cancer3DSMYD3(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM608783   
Orphanet
MedgenSMYD3
Genetic Testing Registry SMYD3
NextProtQ9H7B4 [Medical]
TSGene64754
GENETestsSMYD3
Huge Navigator SMYD3 [HugePedia]
snp3D : Map Gene to Disease64754
BioCentury BCIQSMYD3
ClinGenSMYD3
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD64754
Chemical/Pharm GKB GenePA37972
Clinical trialSMYD3
Miscellaneous
canSAR (ICR)SMYD3 (select the gene name)
Probes
Litterature
PubMed57 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineSMYD3
EVEXSMYD3
GoPubMedSMYD3
iHOPSMYD3
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Feb 2 14:10:43 CET 2017

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.